Darbepoetin

Phase 3Small molecule

Bayer

Darbepoetin is one of 89 small molecule programs targeting Liver Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantRecruiting

CirrhosisActive, not recruiting

Liver TransplantPhase 3

Recruiting

CirrhosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

95 competitors in Liver Transplant

#DrugCompanyPhaseTrials

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

1 2

Prothrombin Complex Concentrate

CSL Behring

Phase 3

1 3

Darbepoetin

Bayer

Phase 3

1 4

Tacrolimus Pill

EEdward Geissler

Phase 3

1 5

Lenvima

Eisai

Preclinical

2 6

Octreotide

Johnson & Johnson

Preclinical

2 7

Beyfortus

BeiGene

Preclinical

1 8

Prostigmin

Merck & Co.

Preclinical

1 9

Myfortic

Novartis

Preclinical

1 10

Cyklokapron

JJ Molner

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Liver Transplant

NCT07169643

Q4 2031

N/ANot yet recruiting

Cirrhosis

NCT07131280

Clinical

Trials by Indication[1]

Cirrhosis2 trials

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT07002827·60 enrolled

National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT07131280·110 enrolled

Myelodysplastic Syndromes2 trials

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Unknown status·GGroupe Francophone des Myelodysplasies·Phase 2·NCT00443339·99 enrolled

Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

Unknown status·SSt. Bartholomew's Hospital·Phase 2/3·NCT00234143·360 enrolled

Nephropathy1 trial

Effect of Darbepoetin in Contrast-induced Nephropathy

Terminated·SSeoul National University Bundang Hospital·Phase 2/3·NCT01197235·80 enrolled

Dialysis1 trial

Long-term Pre-dialysis Extension in Europe and Asia Pacific

Completed· Bayer logo

Bayer·Phase 2·NCT02055482·166 enrolled

Hypertension1 trial

Mechanisms of EPO-induced Hypertension

Terminated·VVA Office of Research and Development·Phase 2·NCT03810911·27 enrolled

2 more indications

Liver Transplant1 trial

Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)

Recruiting·FFundacion Clinic per a la Recerca Biomédica·Phase 3·NCT07169643·140 enrolled

Neurocognitive1 trial

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Completed·NNICHD Neonatal Research Network·Phase 3·NCT03169881·650 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Darbepoetin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Darbepoetin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Darbepoetin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Darbepoetin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2031

Trials by Indication[1]

Cirrhosis2 trials

Myelodysplastic Syndromes2 trials

Nephropathy1 trial

Dialysis1 trial

Hypertension1 trial

Liver Transplant1 trial

Neurocognitive1 trial

References

Drug Info

Quick Facts

Related News